Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries LAWSUITS FILED AGAINST OTLY, LIVE and SAVA - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire September 24, 2021 at 19:30 PM EDT NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.Oatly Group AB (NASDAQ:OTLY)CONTACT JAKUBOWITZ ABOUT OTLY:https://claimyourloss.com/securities/oatly-group-ab-loss-submission-form/?id=19867&from=1Class Period: May 20, 2021 - July 15, 2021Lead Plaintiff Deadline: September 24, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.Live Ventures Incorporated (NASDAQ:LIVE)CONTACT JAKUBOWITZ ABOUT LIVE:https://claimyourloss.com/securities/live-ventures-incorporated-loss-submission-form/?id=19867&from=1Class Period: December 28, 2016 - August 3, 2021Lead Plaintiff Deadline: October 12, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Live's earnings per share for FY 2016 was actually only $6.33 per share; (2) the Company used an artificially low share count to boost the earnings per share by 40%; (3) Live had overstated pretax income for fiscal 2016 by 20% by including $915,500 of "other income" related to certain amendments that were not negotiated until after the close of the fiscal year; (4) Live's acquisition of ApplianceSmart did not close during first quarter 2017; (5) using December 30, 2017 as the "acquisition date" and recognizing income therefrom did not conform to generally accepted accounting principles; (6) by falsely stating that the acquisition closed during the quarter, Live recognized bargain purchase gain, which enabled the Company to report positive net income in what would otherwise have been an unprofitable quarter; (7) between fiscal 2016 and fiscal 2018, Live's CEO received approximately 94% more in compensation than was disclosed to investors; and (8) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Cassava Sciences, Inc. (NASDAQ:SAVA)CONTACT JAKUBOWITZ ABOUT SAVA:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19867&from=1Class Period: February 2, 2021 - August 24, 2021Lead Plaintiff Deadline: October 26, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz Law View source version on accesswire.com: https://www.accesswire.com/665542/LAWSUITS-FILED-AGAINST-OTLY-LIVE-and-SAVA--Jakubowitz-Law-Pursues-Shareholders-Claims Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
LAWSUITS FILED AGAINST OTLY, LIVE and SAVA - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire September 24, 2021 at 19:30 PM EDT NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.Oatly Group AB (NASDAQ:OTLY)CONTACT JAKUBOWITZ ABOUT OTLY:https://claimyourloss.com/securities/oatly-group-ab-loss-submission-form/?id=19867&from=1Class Period: May 20, 2021 - July 15, 2021Lead Plaintiff Deadline: September 24, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.Live Ventures Incorporated (NASDAQ:LIVE)CONTACT JAKUBOWITZ ABOUT LIVE:https://claimyourloss.com/securities/live-ventures-incorporated-loss-submission-form/?id=19867&from=1Class Period: December 28, 2016 - August 3, 2021Lead Plaintiff Deadline: October 12, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Live's earnings per share for FY 2016 was actually only $6.33 per share; (2) the Company used an artificially low share count to boost the earnings per share by 40%; (3) Live had overstated pretax income for fiscal 2016 by 20% by including $915,500 of "other income" related to certain amendments that were not negotiated until after the close of the fiscal year; (4) Live's acquisition of ApplianceSmart did not close during first quarter 2017; (5) using December 30, 2017 as the "acquisition date" and recognizing income therefrom did not conform to generally accepted accounting principles; (6) by falsely stating that the acquisition closed during the quarter, Live recognized bargain purchase gain, which enabled the Company to report positive net income in what would otherwise have been an unprofitable quarter; (7) between fiscal 2016 and fiscal 2018, Live's CEO received approximately 94% more in compensation than was disclosed to investors; and (8) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Cassava Sciences, Inc. (NASDAQ:SAVA)CONTACT JAKUBOWITZ ABOUT SAVA:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19867&from=1Class Period: February 2, 2021 - August 24, 2021Lead Plaintiff Deadline: October 26, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz Law View source version on accesswire.com: https://www.accesswire.com/665542/LAWSUITS-FILED-AGAINST-OTLY-LIVE-and-SAVA--Jakubowitz-Law-Pursues-Shareholders-Claims